Drug manufacturers can’t wave a magic wand and streamline government drug discount programs. Nonetheless, there are actions manufacturers can take to mitigate the impact of noncompliant rebates
Parties in four Medicare payment cut cases filed joint status reports requesting cases be stayed until June 5 in anticipation of HHS expected proposed remedy under AHA v. Becerra. In three Medicare payment cut cases the plaintiff hospitals voluntarily dismissed the case.
In recent years, manufacturers have restricted access to 340B pricing for drugs dispensed through contract pharmacies. The federal government has advised manufacturers that such restrictions are unlawful, and manufactures have challenged government enforcement actions in federal court.
Concerns about who qualifies under the 340B Program, how drugs can be dispensed to patients, and how much entities will be reimbursed may significantly impact the operation of the 340B Program as Congress intended. This evolving landscape poses challenges to all stakeholders.